Doel van het onderzoek: To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). (Primary)
Hoofdonderzoeker: Jonas Paludo, M.D., Mayo Clinic in Rochester, Minnesota, United States
Contactgegevens: Clinical Trials Referral Office Phone: +1-855-776-0015 Email: mayocliniccancerstudies@mayo.edu
Gewenste betrokkenheid van de patiënt: 18 Years and older
ClinicalTrials.gov-identificatiecode: NCT04640779